scispace - formally typeset
M

Mette K. Andersen

Researcher at Copenhagen University Hospital

Publications -  165
Citations -  6963

Mette K. Andersen is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Population & Leukemia. The author has an hindex of 41, co-authored 148 publications receiving 6152 citations. Previous affiliations of Mette K. Andersen include University of Helsinki & Centre national de la recherche scientifique.

Papers
More filters
Journal ArticleDOI

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Fergus J. Couch, +261 more
- 27 Mar 2013 - 
TL;DR: It is estimated that the breast cancer lifetime risks for the5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk, and the ovarian cancer lifetime risk is 63% or higher, based on the known cancer risk-modifying loci.
Journal ArticleDOI

Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis

TL;DR: Mutations with loss of function of p53 are significantly associated with deletion or loss of 5q in t-MDS and t-AML after previous treatment with alkylating agents and are associated with genetic instability.
Journal ArticleDOI

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease

TL;DR: The clinical description of the syndrome has changed little since the original observation, and the cardinal findings of SIADH are as follows: hyponatremia with corresponding hypo‐osmolality of the serum and extracellular fluid, continued renal excretion of sodium, absence of clinical evidence of fluid volume depletion.
Journal ArticleDOI

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.

TL;DR: Therapy-related acute myeloid leukemia (t-AML) in most cases develops after chemotherapy of other malignancies and shows characteristic chromosome aberrations.